Our campaign wins
With your help, we’re making progress for dementia research and people impacted by the condition.
NHS Health Check to include brain health information
MPs heed cry to back dementia research
Our Campaigners help drive support for an Early Day Motion during Dementia Action Week, recognising the impact of dementia and our mission to bring about the first life-changing treatment by 2025. A total of 34 MPs across six political parties sign the Early Day Motion, helping us understand who can champion our cause in parliament.
PM supports revolutionary early diagnosis effort
Prime Minister Theresa May outlines a new early diagnosis of disease project within the Grand Challenge on Artificial Intelligence in the Industrial Strategy and mentions dementia as part of this work. This announcement aligns with work Alzheimer’s Research UK is doing to change the way we detect the diseases that cause dementia.
1,000th Campaigner joins Alzheimer’s Research UK
Alzheimer’s Research UK calls for help promoting dementia research during the snap general election and the number of people helping us campaign soars! Thanks to you, we now have more people calling for support in government than ever before.
Tory manifesto includes dementia pledge
In the midst of a snap general election, the Conservatives’ election manifesto includes a commitment to invest in dementia research. Alzheimer’s Research UK calls on other political parties to make similar commitments to ensure efforts to power breakthroughs in dementia research remain a priority in the next parliament.
Report shows number of dementia researchers has doubled
Following a boost in research investment in 2010, the number of neurodegeneration researchers in the UK doubles between 2008/9 and 2014/15. This also results in a doubling of the number of research publications, increasing our understanding of the diseases that cause dementia.
Alzheimer’s Research UK hosts roundtable to learn from drug failure
In the wake of the disappointing halt of clinical trials into Alzheimer’s drug solanezumab, Alzheimer’s Research UK brings together leading international researchers, including those who worked on the drug, to discuss learnings from the trials. This was the first time that detailed data from the trial was presented to the scientific community, and the discussions are now being used to help shape future research efforts.
Alzheimer’s Research UK joins government to fund groundbreaking research effort
Alzheimer’s Research UK commits £50m to the UK Dementia Research Institute, which is led by a government investment of £150m. The initiative demonstrates a strong commitment to dementia research and is the largest joint effort in the UK supporting dementia research uniting Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK.
Dementia is made a ‘test case’ for treatment evaluations
Following campaigns from Alzheimer’s Research UK, the new Accelerated Access Review names dementia as a ‘test case’ in evaluating new medicines made available on the NHS. The review considers how to speed up access to new drugs, medical technology and diagnostic tools.
New dementia research fund is announced
Alzheimer’s Research UK joins with the UK Department of Health and major pharmaceutical companies to invest in a global fund to develop new treatment approaches. The Dementia Discovery Fund focuses on exploring new ideas in dementia research, as well as stimulating further global investment in research into the condition.
Challenge on Dementia is renewed
Following the publication of Alzheimer’s Research UK’s Manifesto 2015-2020, which lays out steps needed to achieve the goal of bringing about a life-changing treatment by 2025, the coalition government sets out plans for its second Challenge on Dementia. This includes a commitment to investing £300m in dementia research over five years.
Report reveals dementia hits women hardest
Alzheimer’s Research UK publishes “Women and Dementia: A marginalised majority”, a groundbreaking report that looks at how dementia impacts women. This insightful report stimulates conversation around the world and is referenced by organisations including the Global Alliance for Women’s Brain Health.
Prime Minister welcomes research goal at G8 event
Following ambitions set at the G8 Dementia Summit, Alzheimer’s Research UK pledges to raise £100m for dementia research. Among the projects funded is a pioneering UK Stem Cell Research Centre to enable collaboration between researchers at University of Cambridge and University College London. Prime Minister David Cameron announces this campaign in his speech at a legacy event of the G8 Dementia Summit.
G8 sets ambitious goal for dementia research and treatment
The UK government uses its presidency of the G8 to host the first ever G8 Dementia Summit. At the event, world leaders commit to an ambition to develop a disease-modifying treatment for dementia by 2025.
Challenging government to answer to UK dementia crisis
Alzheimer’s Research UK launches its first report on dementia research capacity, “Defeating Dementia”, revealing a serious lack of dementia researchers in the UK and highlighting the need for a national dementia research strategy. Just two months later, the first Prime Minister’s Challenge on Dementia is launched by Prime Minister David Cameron, including a commitment to double research funding in the UK.
New report reveals incredible challenge presented by dementia
The Alzheimer’s Research Trust – soon to be renamed Alzheimer’s Research UK – publishes “Dementia 2010”, which reveals that dementia research is desperately underfunded despite costing the UK economy more than cancer and heart disease combined. This sparks a national discussion about the challenge dementia poses and the need for greater research investment.
Research leads to change in clinical use of antipsychotics
Researchers funded by Alzheimer’s Research UK find that antipsychotic medication, commonly prescribed to people with dementia, can worsen symptoms and double the risk of death. These findings contribute to a 2009 government report pledging to cut the use of antipsychotics by two-thirds and lead to a high-profile campaign to save lives.
Dementia researchers vote against NICE proposals
Over 100 of the UK’s top dementia research scientists gather at Alzheimer’s Research UK’s conference in Nottingham and vote unanimously against proposals by NICE to deny or heavily restrict NHS patient access to Alzheimer’s drugs. This causes NICE to shift their ruling so people with dementia at all stages can benefit from available treatments.